Literature DB >> 7518782

Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro.

P R Gibson1, O Rosella, G Rosella, G P Young.   

Abstract

BACKGROUND/AIMS: Because the neutral protease urokinase is important in control of cell adhesion and migration, the effects of the physiologically relevant fermentation product butyrate on urokinase secretion by colonic epithelium were examined.
METHODS: Secreted and cell-associated levels of urokinase and plasminogen activator inhibitor 1 were measured in colonic crypt cells within 24 hours of isolation from macroscopically normal mucosa of normal or cancer-bearing colons.
RESULTS: Butyrate caused a concentration-dependent inhibition of both secreted (56% +/- 4% inhibition after 24-hour exposure to 1 mmol/L butyrate; n = 20; mean +/- SEM; P < 0.001) and cell-associated urokinase content (35% +/- 6%; P = 0.003). Acetate and propionate had minimal effects. Butyrate also stimulated plasminogen activator inhibitor 1 secretion by 25% +/- 7% (P = 0.013). Net urokinase activities were suppressed in supernates and cell homogenates by butyrate. Levels of transcripts for urokinase and the inhibitor changed with butyrate exposure in parallel to the levels of secretion of the respective proteins. Cells from the cancer group showed significantly reduced inhibitor secretion and abnormal responses to butyrate (greater inhibition of urokinase secretion and no stimulation of inhibitor secretion), probably reflecting the diffuse disturbance of colonic epithelial biology associated with colorectal cancer.
CONCLUSIONS: Butyrate has dual effects in markedly reducing colonic epithelial urokinase activity, and these may have important implications to understanding colonic epithelial physiology and the pathogenesis and treatment of colonic diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518782     DOI: 10.1016/0016-5085(94)90166-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.

Authors:  M Goh; F Chen; M T Paulsen; A M Yeager; E S Dyer; M Ljungman
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

Review 2.  Butyrate and the colonocyte. Implications for neoplasia.

Authors:  O C Velázquez; H M Lederer; J L Rombeau
Journal:  Dig Dis Sci       Date:  1996-04       Impact factor: 3.199

3.  Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover.

Authors:  P R Gibson; I Birchall; O Rosella; V Albert; C F Finch; D H Barkla; G P Young
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

4.  Colonic epithelium is diffusely abnormal in ulcerative colitis and colorectal cancer.

Authors:  P Gibson; O Rosella; R Nov; G Young
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

5.  Intrapleural fibrinolytic treatment of multiloculated pediatric empyemas.

Authors:  Refik Ulkü; Abdurrahman Onen; Serdar Onat; Nihal Kilinç; Cemal Ozçelik
Journal:  Pediatr Surg Int       Date:  2004-06-08       Impact factor: 1.827

6.  Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease.

Authors:  P Gibson; O Rosella
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

7.  Exploring Human Milk Dynamics: Interindividual Variation in Milk Proteome, Peptidome, and Metabolome.

Authors:  Pieter M Dekker; Sjef Boeren; Johannes B van Goudoever; Jacques J M Vervoort; Kasper A Hettinga
Journal:  J Proteome Res       Date:  2022-02-01       Impact factor: 4.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.